目的 探讨血脂康胶囊联合普伐他汀钠片治疗慢性心力衰竭的临床疗效。方法 选取2020年6月—2022年2月在天津市第三中心医院分院就诊的78例慢性心力衰竭患者，根据随机数字表法将78例患者分为对照组和治疗组，每组各39例。对照组口服普伐他汀钠片，20 mg/次，1次/d。治疗组在对照组基础上口服血脂康胶囊，2粒/次，2次/d。两组患者连续治疗1个月。观察两组的临床疗效，比较两组心功能指标、生活质量和血清N末端B型利钠肽原（NT-ProBNP）、白细胞介素-6（IL-6）、肿瘤坏死因子-α（TNF-α）水平。结果 治疗后，治疗组的总有效率为92.31%，显著高于对照组的总有效率74.36%，差异有显著性（P＜0.05）。治疗后，两组的左室射血分数（LVEF）、心输出量（CO）明显增加，左心室收缩末期内径（LVESD）明显减少（P＜0.05）；治疗后治疗组的LVEF、CO比对照组高，LVESD比对照组低（P＜0.05）。治疗后，两组的明尼苏达生活质量量表（MLHFQ）评分较治疗前明显降低（P＜0.05），并且治疗组患者MLHFQ评分明显低于对照组（P＜0.05）。治疗后，两组的血清NT-ProBNP、IL-6、TNF-α水平较治疗前降低（P＜0.05），且治疗组的血清NT-ProBNP、IL-6、TNF-α水平均低于对照组（P＜0.05）。结论 血脂康胶囊联合普伐他汀钠片治疗慢性心力衰竭的疗效确切，能改善患者心功能和生活质量，降低炎症反应，降低心肌损伤，并且药物安全性较好。

Objective To investigate the efficacy of Xuezhikang Capsules combined with Pravastatin Sodium Tablets in treatment of chronic heart failure.Methods Patients (78 cases) with chronic heart failure in the Branch of Tianjin Third Central Hospital from June 2020 to February 2022 were divided into control and treatment groups according to the random number table method,and each group had 39 cases.Patients in the control group were po administered with Pravastatin Sodium Tablets,20 mg/time,once daily.Patients in the treatment group were po administered with Xuezhikang Capsules on the basis of the control group,2 grains/time,twice daily.Patients in two groups were treated for 1 month.After treatment,the clinical efficacies were evaluated,and the cardiac function index,the quality of life,and the serum levels of NT-ProBNP,IL-6,and TNF-α in two groups were compared.Results After treatment,the total effective rate of the treatment group was 92.31%,which was significantly higher than 74.36% of the control group (P<0.05).After treatment,the LVEF and CO in two groups were significantly increased,but the LVESD in two groups were significantly decreased (P<0.05).After treatment,the LVEF and CO in the treatment group were higher than those in the control group,but the LVESD in the treatment group was lower than those in the control group (P<0.05).After treatment,the MLHFQ score of two groups was significantly lower than that before treatment (P<0.05),and the MLHFQ score of the treatment group was significantly lower than that of the control group (P<0.05).After treatment,the levels of NT-ProBNP,IL-6,and TNF-α in two groups were lower than those before treatment (P<0.05),and the levels of NT-ProBNP,IL-6,and TNF-α in the treatment group were lower than those in the control group (P<0.05).Conclusion Xuezhikang Capsules combined with Pravastatin Sodium Tablets has clinical curative effect in treatment of chronic heart failure,can improve patients'cardiac function and quality of life,reduce inflammatory reaction,reduce myocardial injury,with good safety.

R972